Surface modified polymeric nanoparticles for drug delivery: preparation and applications

2020 ◽  
Vol 14 ◽  
Author(s):  
Garima Joshi ◽  
Krutika Sawant ◽  
Mitali Patel ◽  
Deepak Chaudhary
Keyword(s):  
Drug Delivery ◽  
Targeted Delivery ◽  
Surface Engineering ◽  
Polymeric Nanoparticles ◽  
Biochemical Properties ◽  
Site Of Action ◽  
Hiv Drugs ◽  
Surface Modified ◽  
Surface Modified Nanoparticles ◽  
Anti Hiv

: Nanotechnology is one of the emerging fields in the drug delivery for targeting the drug to the site of action. The polymeric nanoparticles as drug delivery systems have gained importance for the last few decades. They offer advantages over liposomes, dendrimers, emulsions etc. Surface engineering of polymeric nanoparticles is widely utilized to effectively target the cells in various diseases such as cancer, HIV infection. Surface modified nanoparticles offer various advantages such as targeted drug delivery, reduction in side effects, dose reductionand improved therapeutic efficacy. Moreover, they can aid in improving physical and biochemical properties, pharmacokinetic and pharmacodynamic profiles of drug. Surface modified polymeric nanoparticles can provide targeted delivery of drugs into specific cells, especially when targets are intracellular localized. This approach would be more advantageous for the delivery of various anticancer, anti inflammatory, anti HIV drugs for more effective therapy. This review focuses on the techniques used for fabrication of polymeric nanoparticles, material used for surface modification and their applications.

Recent Advances in Drug Delivery Strategies for Improved Therapeutic Efficacy of Efavirenz

2020 ◽  
Vol 14 (2) ◽  
pp. 119-127
Author(s):  
Mitali Patel ◽  
Ruhi Shah ◽  
Krutika Sawant
Keyword(s):  
Drug Delivery ◽  
Controlled Release ◽  
Therapeutic Efficacy ◽  
Water Solubility ◽  
Polymeric Nanoparticles ◽  
Solid Dispersions ◽  
Engineered Nanoparticles ◽  
Recent Advances ◽  
Hiv Drugs ◽  
Anti Hiv

Background: Efavirenz, an anti-HIV agent, has a noticeable place in the HAART regimen for the treatment and maintenance therapy of AIDS. However, its poor water solubility accounts for hindered absorption and bio-distribution upon administration. This results in its low and variable bioavailability. To circumvent these limitations, various novel formulations of Efavirenz have been investigated in order to mitigate its drawbacks and draw out its maximum therapeutic effect. Methods: Numerous formulations explored to overcome the drawbacks of Efavirenz include modified/ controlled-release tablets, solid dispersions, polymeric nanoparticles, dendrimers, surface-engineered nanoparticles and various other nanoformulations. Moreover, combinatorial formulations of Efavirenz with other Anti-HIV drugs have also been reported to overcome the problem of Drug-Resistance. Results: The nanoformulation based strategies, owing to their ability to provide controlled release profile and targeted drug delivery were found to augment bioavailability, therapeutic efficacy and reduce the side effects of the Efavirenz. Conclusion: This review pivots around the challenges and recent advances in the delivery of Efavirenz with particular emphasis on novel formulations including its patents.

scholarly journals A New Approach to Developing Long-Acting Injectable Formulations of Anti-HIV Drugs: Poly(Ethylene Phosphoric Acid) Block Copolymers Increase the Efficiency of Tenofovir against HIV-1 in MT-4 Cells

2020 ◽  
Vol 22 (1) ◽  
pp. 340
Author(s):  
Ilya Nifant’ev ◽  
Andrei Siniavin ◽  
Eduard Karamov ◽  
Maxim Kosarev ◽  
Sergey Kovalchuk ◽  
...  
Keyword(s):  
Controlled Release ◽  
Block Copolymers ◽  
Phosphoric Acid ◽  
Hiv Infection ◽  
Targeted Delivery ◽  
Release Formulation ◽  
Poly Ethylene ◽  
Long Acting ◽  
Hiv Drugs ◽  
Anti Hiv

Despite the world’s combined efforts, human immunodeficiency virus (HIV), the causative agent of AIDS, remains one of the world’s most serious public health challenges. High genetic variability of HIV complicates the development of anti-HIV vaccine, and there is an actual clinical need for increasing the efficiency of anti-HIV drugs in terms of targeted delivery and controlled release. Tenofovir (TFV), a nucleotide-analog reverse transcriptase inhibitor, has gained wide acceptance as a drug for pre-exposure prophylaxis or treatment of HIV infection. In our study, we explored the potential of tenofovir disoproxil (TFD) adducts with block copolymers of poly(ethylene glycol) monomethyl ether and poly(ethylene phosphoric acid) (mPEG-b-PEPA) as candidates for developing a long-acting/controlled-release formulation of TFV. Two types of mPEG-b-PEPA with numbers of ethylene phosphoric acid (EPA) fragments of 13 and 49 were synthesized by catalytic ring-opening polymerization, and used for preparing four types of adducts with TFD. Antiviral activity of [mPEG-b-PEPA]TFD or tenofovir disoproxil fumarate (TDF) was evaluated using the model of experimental HIV infection in vitro (MT-4/HIV-1IIIB). Judging by the values of the selectivity index (SI), TFD exhibited an up to 14-fold higher anti-HIV activity in the form of mPEG-b-PEPA adducts, thus demonstrating significant promise for further development of long-acting/controlled-release injectable TFV formulations.

Advancement in nano pharmaceutical formulation and their biomedical use

2020 ◽  
Vol 10 ◽  
Author(s):  
Dharmendra Kumar ◽  
Rishabha Malviya ◽  
Pramod kumar Sharma ◽  
Akanksha Sharma ◽  
Vineet Bhardwaj
Keyword(s):  
Drug Delivery ◽  
Water Solubility ◽  
Polymeric Micelles ◽  
Medical Sciences ◽  
Organic Nanoparticles ◽  
Drug Delivery Carrier ◽  
Block Ionomer Complexes ◽  
Block Ionomer ◽  
Surface Modified ◽  
Surface Modified Nanoparticles

: Nanoparticles and modified nanoparticles are used in biological and medical sciences as liposomes, polymeric micelles, block ionomer complexes, dendrimers, inorganic and organic nanoparticles. Nanoparticles and surface modified nanoparticles are showed good stability and water solubility and can be used efficiently as drug delivery carrier. This paper summarized the advancement in nanoparticles/surface modified nanoparticles and patents based on them.

scholarly journals Brain Disposition of Antibody-Based Therapeutics: Dogma, Approaches and Perspectives

2021 ◽  
Vol 22 (12) ◽  
pp. 6442
Author(s):  
Aida Kouhi ◽  
Vyshnavi Pachipulusu ◽  
Talya Kapenstein ◽  
Peisheng Hu ◽  
Alan L. Epstein ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Targeted Delivery ◽  
Neurological Diseases ◽  
High Specificity ◽  
Biochemical Properties ◽  
Antibody Engineering ◽  
Stage Of Development ◽  
The Central Nervous System ◽  
Underlying Mechanisms ◽  
The Brain

Due to their high specificity, monoclonal antibodies have been widely investigated for their application in drug delivery to the central nervous system (CNS) for the treatment of neurological diseases such as stroke, Alzheimer’s, and Parkinson’s disease. Research in the past few decades has revealed that one of the biggest challenges in the development of antibodies for drug delivery to the CNS is the presence of blood–brain barrier (BBB), which acts to restrict drug delivery and contributes to the limited uptake (0.1–0.2% of injected dose) of circulating antibodies into the brain. This article reviews the various methods currently used for antibody delivery to the CNS at the preclinical stage of development and the underlying mechanisms of BBB penetration. It also describes efforts to improve or modulate the physicochemical and biochemical properties of antibodies (e.g., charge, Fc receptor binding affinity, and target affinity), to adapt their pharmacokinetics (PK), and to influence their distribution and disposition into the brain. Finally, a distinction is made between approaches that seek to modify BBB permeability and those that use a physiological approach or antibody engineering to increase uptake in the CNS. Although there are currently inherent difficulties in developing safe and efficacious antibodies that will cross the BBB, the future prospects of brain-targeted delivery of antibody-based agents are believed to be excellent.

Surface-Modified Nanoparticles to Improve Drug Delivery

2014 ◽  
pp. 1-7
Author(s):  
Felipe Oyarzun-Ampuero ◽  
Marcelo J. Kogan ◽  
Andrónico Neira-Carrillo ◽  
Javier O. Morales
Keyword(s):  
Drug Delivery ◽  
Surface Modified ◽  
Surface Modified Nanoparticles ◽  
Improve Drug Delivery

Surface-modified polymeric nanoparticles for drug delivery to cancer cells

2020 ◽  
Vol 18 (1) ◽  
pp. 1-24
Author(s):  
Arsalan Ahmed ◽  
Shumaila Sarwar ◽  
Yong Hu ◽  
Muhammad Usman Munir ◽  
Muhammad Farrukh Nisar ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Cancer Cells ◽  
Polymeric Nanoparticles ◽  
Surface Modified

Drug delivery approaches for anti-HIV drugs

1993 ◽  
Vol 95 (1-3) ◽  
pp. 1-21 ◽  
Author(s):  
Haresh Mirchandani ◽  
Yie W. Chien
Keyword(s):  
Drug Delivery ◽  
Hiv Drugs ◽  
Anti Hiv

Bioerodible Polymeric Nanoparticles for Targeted Delivery of Proteic Drugs

2006 ◽  
Vol 6 (9) ◽  
pp. 3040-3047 ◽  
Author(s):  
Elisabetta E. Chiellini ◽  
Federica Chiellini ◽  
Roberto Solaro
Keyword(s):  
Drug Delivery ◽  
Targeted Delivery ◽  
Polymeric Nanoparticles ◽  
Hybrid Nanoparticles ◽  
Polymeric Systems ◽  
Nanoparticle Surface ◽  
Biological Tests ◽  
Targeting Ability ◽  
Average Size ◽  
Targeted Release

Significant efforts are being devoted to develop nanotechnology for drug delivery, mainly because of the distinct advantages offered by nanometer-size polymeric systems. Moreover, targeted drug delivery can be obtained by polymer conjugation to biospecific ligands. The present investigation was aimed mainly at determining the targeting ability of hybrid nanoparticles based on synthetic polymer/protein hybrid matrices. These nanoparticles were designed for liver targeted release of proteic drugs with antiviral activity, such as α-interferon. Human serum albumin and the monoesters of alternating copolymers of maleic anhydride/alkyl vinyl ethers of oligo(ethylene glycol) were selected as proteic and synthetic components, respectively. Digalactosyl diacyl glycerol, a natural glycolipid selectively recognized by the asialofetuin receptor present on liver hepatocytes was used as active targeting agent. Nanoparticles of 100–300 nm average size were obtained by controlled coprecipitation method. Investigation of nanoparticle surface properties by spectroscopic analysis and by biological tests indicated that the synthesized nanoparticles do expose on their surface targeting moieties that selectively interact with liver hepatocytes receptors.

Sign in / Sign up

Export Citation Format

Share Document